EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Trial to side effects compliance and response of 5 aminosalicylic acid mesalazine during the treatment of ulcerative colitis and crohn's disease






Leber Magen Darm 18(2): 104, 106-108, 111-113

Trial to side effects compliance and response of 5 aminosalicylic acid mesalazine during the treatment of ulcerative colitis and crohn's disease

In an open clinical trial 71 patients with ulcerative colitis and 27 patients with Crohn's disease were treated with mesalazine (5-ASA). After four to eight weeks of acute phase treatment, maintenance therapy was ensued by treatment over a period of maximal 48 weeks. The activity of both inflammatory bowel diseases clearly decreased. Relapse was not observed during maintenance treatment in ulcerative colitis. Pathological changes of clincial findings were not observed during treatment. Pathologic changes before treatment, which were associated with the disease, returned to normal during treatment. All potential side effects during treatment were recorded. The rate of side effects was low and all normalized when therapy was continued. The study confirms that mesalazine was safe, efficient and almost well tolerated.


Accession: 006840592



Related references

Drug safety, acceptance and effectiveness of 5-aminosalicylic acid (mesalazine) in the treatment of ulcerative colitis and Crohn disease. Leber, Magen, Darm 18(2): 104-113, 1988

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Bmj 298(6666): 82-86, 1989

Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis - results from a randomized-controlled trial. Alimentary Pharmacology and Therapeutics 20(11-12): 1353-1363, 2004

5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease. Tidsskrift for den Norske Laegeforening 123(18): 2565-2567, 2004

A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis. Digestion 29(4): 204-208, 1984

Coated mesalazine 5 aminosalicylic acid versus sulfasalazine in the treatment of active ulcerative colitis a randomized trail. British Medical Journal 298(6666): 82-86, 1989

Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. Alimentary Pharmacology & Therapeutics 33(9): 996-1009, 2011

Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 94(6): 1383-1389, 1988

Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial. Digestive and Liver Disease 34(11): 787-793, 2003

Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: One-year randomised multicentre trial. Digestive and Liver Disease 34(11): 787-793, 2002